Company intelligence / Profile preview

Signati Medical

Providence, Rhode Island, United Stateslinkedin.com ↗

Ownership: Private
Development stage: NDA

Overview

Signati Medical has completed a first-in-human Investigational Device Exemption (IDE) clinical trial of its proprietary Separo™ Vessel Sealing System for vasectomy. The study enrolled eight patients and met its primary endpoint with no device-related adverse events. The company is now preparing a De Novo submission to the FDA seeking market clearance. The device is not yet approved or marketed in any country.

Therapeutic areas: Women's HealthMen's Health
Modalities: Device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Separo Vessel Sealing System

NDA

Indications: Vasectomy

Beyond the preview

Go deeper on Signati Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Signati Medical.

Explore the full profile